



PREPARATION AND EVALUATION OF MICROPARTICLES CONTAINING SOTALOL HYDROCHLORIDE USING NATURAL POLYMERS FOR CONTROLLED RELEASE

*Nagendra R., Charan C. S., K. Hanumanthachar Joshi and Jayanthi C.

Department of Pharmaceutics, Sarada Vilas College of Pharmacy Mysuru, Karnataka.

*Corresponding Author: Nagendra R.

Department of Pharmaceutics, Sarada Vilas College of Pharmacy Mysuru, Karnataka.

Article Received on 09/02/2019

Article Revised on 01/03/2019

Article Accepted on 23/03/2019

ABSTRACT

The present study aimed at preparation and Evaluation of microparticles for controlled release of Sotalol Hydrochloride using natural polymers in the treatment of Arrhythmia. Sotalol has both beta-adrenoreceptor blocking and cardiac action potential duration prolongation and antiarrhythmic properties. The microparticles of Sotalol Hydrochloride were prepared by ionic cross linking method. The prepared microparticles were evaluated for drug polymer compatibility, the results shown that there were no significant interactions. The encapsulation efficacy was ranging from 67-98%. The *in-vitro* drug release studies indicate the release of drug in a controlled manner over a period of 12 hrs. It was found that the Sotalol Hydrochloride release rate increased with a decreased amount of Guar gum since the drug is water soluble. This can be adjusted by maintaining the concentration of the natural polymers. The formulation F5 was found to be optimum formulation.

KEYWORDS: Sotalol Hydrochloride, Arrhythmia, guar gum, Xanthan gum Controlled release.

INTRODUCTION

Controlled drug delivery systems containing polymeric carriers has gained increased interest in last two decades, because they can be fabricated into films, rods capsules and microparticles^[1] they mask the unacceptable taste or odor of drugs, they stabilize drugs sensitive to oxygen, moisture or light, they eliminate incompatibilities among drugs.

Sotalol has both beta-adrenoreceptor blocking (Vaughan Williams Class I) and cardiac action potential duration prolongation (Vaughan Williams Class I) antiarrhythmic properties. Sotalol inhibits response to adrenergic stimuli by competitively blocking β_1 -adrenergic receptors within the myocardium and β_2 -adrenergic receptors within bronchial and vascular smooth muscle. The electrophysiologic effects of sotalol may be due to its selective inhibition of the rapidly activating component of the potassium channel involved in the repolarization of cardiac cells. The class II electrophysiologic effects are caused by an increase in sinus cycle length (slowed heart rate), decreased AV nodal conduction, and increased AV nodal refractoriness, while the class III electrophysiological effects include prolongation of the atrial and ventricular monophasic action potentials, and effective refractory period prolongation of atrial muscle, ventricular muscle, and atrio-ventricular accessory pathways (where present) in both the anterograde and retrograde directions.^[2] Here an attempt was made to reduce the dosing frequency and to maintain the drug

level at therapeutic concentration range, by formulating a Controlled drug delivery system in the form of microparticles using blend of hydrophilic and lipophilic natural polymers.

METHODS

Preparation of microparticles

The microspheres were prepared by ionic cross-linking technique. The alginate solution comprising 2.5% sodium alginate, 0.25-0.75% hydrophilic polymer and 100mg of drug were prepared by initially dissolving the polymer in 50% deionized water using gentle heat. On complete dissolution the weighed quantity of drug was add mixed thoroughly and to this solution of sodium alginate were added to afford homogeneous dispersion. The dispersion was added drop wise via 20 gauge hypodermic needle fitted with a 10ml syringe into 50ml 5%w/v of cross linking agent (Calcium chloride) solution, being stirred at 200rpm for 10min. The droplets from the dispersion instantaneously gelled into discrete drug-polymer-alginate matrices upon contact with the solution of cross-linking agent. The formed microspheres were further allowed to stir in the solution of cross-linking agent for an additional of 2hrs. On expiration, cross-linking agent was decanted and microspheres were washed with 3 x 50ml volume of deionized water. The microspheres were there after dried at 80° C for 2hrs in a hot air oven.

Table 1: Formulation chart of Sotalol Hydrochloride microparticles using natural polymers.

Formulation No.	Ingredients in (mg/ml)				
	Sotalol hydrochloride	Sodium Alginate (% w/v)	Guar Gum (% w/v)	Xanthan Gum (% w/v)	Calcium Chloride (% w/v)
F1	25	2.5	0.25	-	5
F2	25	2.5	0.50	-	5
F3	25	2.5	0.75	-	5
F4	25	2.5	-	0.25	5
F5	25	2.5	-	0.50	5
F6	25	2.5	-	0.75	5

Differential Scanning Calorimetry (DSC)

DSC is a technique in which the difference in heat flow between the sample and a reference is recorded versus temperature. All dynamic DSC studies were carried out on Du Pont thermal analyzer with 2010 DSC module. Calorimetric measurements were made with empty cell as the reference. The instrument was calibrated using high purity indium metal as standard. The dynamic scans were taken in nitrogen atmosphere at the heating rate of 10° C/Min. The runs were made in triplicate. The scanning temperature for reference pure drug and formulation are the same when dynamic measurements are performed, and hence the required heat energy for chemical transformation is directly recorded on a heat flow versus temperature graph. The energy is measured as Joules per kilocalorie.^[5,6]

Drug loading and encapsulation efficiency

100 mg of microparticles were weighed and transferred to 100 ml volumetric flask containing pH 7.4 phosphate buffer. From this, 1 ml of solution was transferred to 10 ml volumetric flask and diluted up to the mark. Further 1 ml of this solution was diluted to 10 ml and absorbance was measured. The drug content was calculated by using the formula.^[7,8]

Amount of drug = $\frac{\text{Conc. from standard graph} \times \text{dilution factor}}{1000}$

Percentage encapsulation efficiency is found out by calculating the amount of drug present in 100 mg of microparticles. It is further calculated by using formula

$$\% \text{ Encapsulation Efficiency} = \frac{b}{a} \times 100$$


Where, 'a' is the theoretical drug content and 'b' is the drug entrapped.

In vitro drug release studies

Release of Sotalol Hydrochloride was determined using dissolution test apparatus USP type II at 100 rpm. The dissolution was studied using 900 ml of 0.1 N HCl, phosphate buffer 5.5, phosphate buffer pH 7.2. The temperature was maintained at 37±0.5°C. Aliquots (10 ml) of dissolution media were sampled at specified time intervals and replaced with fresh media immediately after sampling. Samples were analyzed for drug content by UV Visible spectroscopy.^[9,10]

RESULTS AND DISCUSSION**Drug-excipient Compatibility Studies**

The compatibility of drug and polymers under experimental conditions is important prerequisite before formulation. It is therefore necessary to confirm that the drug does not react with the polymers and excipients under experimental conditions and affect the shelf life of product or any other unwanted effects on the formulation. The DSC thermograms of the pure drug and formulation were taken, the obtained results indicates that there were no significant interactions between drug and polymer.

**Figure 1: DSC Thermograms of pure drug and the formulation.**

Drug loading and encapsulation efficiency

The test for drug content was carried out to ascertain uniform distribution of the drug in the formulation. Drug loading and entrapment efficiency increase with increase in the polymer concentration. From the results it can be inferred that there is a proper distribution of Sotalol

Hydrochloride in the microparticles and the deviation is within the acceptable limits. The decrease in the drug content in the product probably can be due to the loss of drug with the evaporation of the solvent.


Table 2: Drug loading and encapsulation efficiency of prepared microparticles.

Formulation	Drug loading (%) mean \pm SD*	Encapsulation efficiency (%) mean \pm SD*
F1	51.74 \pm 0.28	93.23 \pm 0.38
F2	32.23 \pm 0.18	70.43 \pm 0.28
F3	47.68 \pm 0.24	67.80 \pm 0.24
F4	33.85 \pm 0.21	46.41 \pm 0.17
F5	57.38 \pm 0.29	98.96 \pm 0.21
F6	49.82 \pm 0.27	76.36 \pm 0.19

In-vitro drug dissolution

Release of Sotalol Hydrochloride was determined using dissolution test apparatus USP type II at 100 rpm. The dissolution was studied using 900 ml of 0.1 N HCl, phosphate buffer 5.5, phosphate buffer pH 7.2. The temperature was maintained at 37 \pm 0.5 $^{\circ}$ C. The sample were withdrawn at different time intervals 1,2,3,4,6,8,10

and 12 hrs filtered through whatman filter paper and replaced equal volume of dissolution medium. Sample was suitably diluted and analyzed for Sotalol Hydrochloride using UV-visible spectrophotometer. The percentage of Sotalol Hydrochloride release was calculated.

**Figure 2: In-vitro drug release profile of the formulations.****CONCLUSION**

The objective of this study was to prepare and evaluate microparticles loaded with Sotalol Hydrochloride for controlled release using different ratios of drug to natural polymers and prepared microparticles were characterized. The method is simple, rapid, and economical and does not imply the use of toxic organic solvents. The method used was suitable for both water-soluble and insoluble drugs. The formulation (F5) produced discrete spherical microparticles. The DSC thermogram obtained for the pure drug and formulation shows no significant shift in the endothermic peaks confirming the stability of the drug in the formulation. From the results of drug loading and encapsulation efficiency, it can be inferred that there was a proper and uniform distribution of drug in the micro particles. The

in vitro drug release data showed the release of a drug in a controlled manner.

ACKNOWLEDGEMENT

We thank principal Sarada Vilas College of Pharmacy and Management Sarada Vilas Educational Institutions for providing facilities.

REFERENCES

1. Brahmkar DM, Jaiswal SB. Biopharmaceutics and pharmacokinetics a treatise, 2nd ed, Vallabh prakashan, 2010; 397–515.
2. J.A, Bakan J.L. Anderson, "Microencapsulation Part III" through Lachman. L, Lieberman H. A, Kanig J. L. The Theory and Practice of Industrial Pharmacy, Varghese Publishing House, Bombay-14, 1986; 2: 428.

3. BK Kim, S J Hwang, Park JB and HJ Park. "Preparation and characterization of drug loaded polymethacrylate microspheres by an emulsion solvent evaporation method." *J microencapsulation*, 2002; 811-22.
4. AA.Du Pasquier "Differential Scanning Calorimetry studies of lithium ion and the reactivity of carbon anodes in plastic lithium ion batteries." *J. Electrochem. Sci.*, 1998; 145(2): 472-477.
5. PB, Deasy Law MFL. "Use of extrusion spherization to develop an improved oral dosage form of indomethacin". *Int. J. Pharm.*, 1997; 201-209.
6. XYan RA.Gemeinhart "Cisplatin delivery from Poly(acrylic acid-co-methyl methacrylate) microparticles," *J. Control Release*, 2005; 106: 198-208.
7. S. kumara, A.K sahaa and K.S Kumar "Preparation and characterization of indomethacin loaded ionically crosslinked microspheres using chitosan." *Scholars Research Library*, 2012; 4(1): 33-41.
8. S. Abreu1M. M. C. Forte 2 , T. B. L. Kist3 L. P. Honaiser "Effect of the preparation method on the drug loading of alginate-chitosan microspheres" *Express Polymer Letters*, 2010; 4(8): 456-464.
9. K S Rangasamy, M Kugalur, G Natesan., "Formulation and evaluation of sustained release tablets of aceclofenac using hydrophilic matrix system". *Int J Pharm Tech Res.*, 2010; 2(3): 1775-80.
10. Indian Pharmacopoeia, Government of India. Ministry of Health and Family Welfare. Delhi: The controller of Publications, 1996: 736.